Diffuse large B-cell lymphoma · 10 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
O-miniCHOP Variant #01 | — | R 917 633 | 21d | — | — | ~6 | ~R 5 505 797 indirect | — |
R-CDOP Variant #01 | — | R 38 439 | 21d | — | — | ~6 | ~R 230 634 indirect | — |
R-GCVP Variant #01 | — | R 36 478 | 21d | — | — | ~6 | ~R 178 738 indirect | — |
Bendamustine and Rituximab (BR) Variant #01 | — | R 33 874 | 28d | — | ~9.5 mo | ~7 | ~R 237 120 PFS proxy · indirect | 1 |
R-BL Variant #01 | — | R 33 396 | 28d | — | — | ~6 | ~R 200 374 indirect | — |
R-CEOP90 Variant #01 | — | R 28 616 | 21d | — | — | 8 | R 223 508 PFS proxy | 2 |
R-CEOP (Etoposide) Variant #01 | — | R 27 465 | 21d | — | — | ~6 | ~R 164 789 indirect | — |
R-MegaCHOP Variant #01 | — | R 27 305 | 21d | — | — | ~3 | ~R 81 914 indirect | — |
R-miniCHOP Variant #01 | — | R 26 464 | 21d | — | — | ~6 | ~R 158 785 indirect | — |
Helicobacter pylori eradication therapy Partial | — | — | — | — | — | — | — | — |
10 of 10 regimens shown